Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Withdrawn 2Terminated 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 8Sarcoma 4Breast 4Genitourinary 2Plasma cell 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Breast Neoplasms 4Sarcoma 1Prostatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Breast Diseases 1

Interventions

Trastuzumab 696Paclitaxel 679Cyclophosphamide 634Docetaxel 554Capecitabine 468Letrozole 407Carboplatin 393Fulvestrant 379Doxorubicin 330Tamoxifen 288pembrolizumab 272Anastrozole 252Epirubicin 249exemestane 238pertuzumab 229Bevacizumab 214Radiotherapy 213Gemcitabine 211Vinorelbine 188palbociclib 183Lapatinib 175130-nm albumin-bound paclitaxel 168Albumin-Bound Paclitaxel 156Exercise 147Magnetic Resonance Spectroscopy 145eribulin 144Taxes 134Fluorouracil 131Everolimus 118Cisplatin 118

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × figitumumab × Breast × Clear all
NCT00372996 2015-10-28

Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer

Pfizer

Phase 2 Terminated
219 enrolled 11 charts
Breast

Breast Neoplasms

NCT00678626 2015-05-04

Phase 2 Trial Of CP-751,871 And Docetaxel In Advanced Breast Cancer

Pfizer

Phase 2 Withdrawn
Breast

Breast Diseases, Breast Neoplasms

NCT00635245 2015-03-11

CP-751871 In Treating Women With Early-Stage Breast Cancer That Can Be Removed By Surgery

Pfizer

Phase 1 Withdrawn
Breast

Breast Neoplasms

NCT00976508 2013-12-13

Figitumumab Combined With Pegvisomant For Advanced Solid Tumors

Pfizer

Phase 1 Terminated
24 enrolled 10 charts
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡